Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: May 10, 2017
Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study.
Journal: Clinical pharmacology in drug development
Published: May 11, 2016
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Journal: Bioorganic & medicinal chemistry letters
Published: September 16, 2015
Metabolism, Excretion and Pharmacokinetics of MLN3897, a CCR1 Antagonist, in Humans.
Journal: Drug metabolism letters
Published: February 17, 2015
Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Journal: Biopharmaceutics & drug disposition
Published: April 28, 2014
Synthesis of isotope-labeled HSP90 inhibitor: [(13) CD3 ] and [(14) C]-TAK-459.
Journal: Journal of labelled compounds & radiopharmaceuticals
Published: April 17, 2014
Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.
Journal: Journal of labelled compounds & radiopharmaceuticals
Published: March 13, 2013
Synthesis of isotopically labeled versions of L-MTP-PE (mifamurtide) and MDP.
Journal: Journal of labelled compounds & radiopharmaceuticals
Published: March 01, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026